InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, today announced that it, together with its PsychedelicNewsWire (“PNW”) brand, will be collaborating with Microdose Psychedelic Insights for upcoming June conferences. The events slated for later this month include the MDMA Conference, set to be held on June 15, 2021, as well as the Psychedelic Capital Conference, taking place on June 30, 2021. The virtual MDMA Conference will explore the potential of MDMA at the intersection of drug development and safety, clinical care and applications, law and regulation, business and markets, science and research, as well as history and culture. The Psychedelic Capital Conference, also taking place in an entirely virtual format, will showcase the top companies, latest IPOs, newest opportunities and deepest industry insights. “We are pleased to collaborate with the InvestorBrandNetwork and its PsychedelicNewsWire brand,” said Kristina Spionjak, organizer of Microdose Events. “Their powerful tools and communication solutions create a robust online presence, which strengthens the already valuable connections our team creates between executives, investors and psychedelic enthusiasts. We are excited to be hosting the MDMA and Psychedelic Capital Conferences, two standout events in a rapidly evolving sector, and we believe that IBN’s assistance in helping us reach a broader audience will be invaluable.”
To view the full press release, visit https://ibn.fm/cyrR9
About Microdose Psychedelics Insights
Microdose Psychedelic Insights is your guide to the psychedelic medicine industry. With a vision to shift the world’s perception of psychedelic medicine, it distributes and creates the most compelling content, financial analysis, engaging events, and groundbreaking education to drive the psychedelics industry to the forefront of modern medicine. For more information, visit www.Microdose.buzz.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
The Psychedelic Therapeutics and Drug Development announced that PsychedelicNewsWire (“PNW), a specialized communications platform for…
Arrowhead Sci-Tech Conferences and Events today announced the 4th Annual Psychedelic Therapeutics and Drug Development…
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a…
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative…
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) today provided an update by way of a…
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) today provided an update by way of a…